EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN HIGH‐RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS

Saved in:
Bibliographic Details
Published in:Hematological oncology 2023-06, Vol.41 (S2), p.125-127
Main Authors: Belada, D., Falchi, L., Leppä, S., Vermaat, J. S., Holte, H., Hutchings, M., Lugtenburg, P., de Vos, S., Abrisqueta, P., Nijland, M., Merryman, R. W., Christensen, J. H., Wahlin, B. E., Linton, K. M., Wang, L., Abbas, A., Rana, A., Quadri, S., Sureda, A.
Format: Article
Language:English
Subjects:
Lymphoma
Rituximab
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.3163_84